Author:
Daniel P,Filiz G,Brown D V,Hollande F,Gonzales M,D’Abaco G,Papalexis N,Phillips W A,Malaterre J,Ramsay R G,Mantamadiotis T
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Molecular Biology
Reference63 articles.
1. Hegi ME, Diserens A-C, Gorlia T, Hamou MF, de Tribolet N, Weller M et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. New Engl J Med 2005; 352: 997–1003.
2. Gilbert MR, Dignam J, Won M, Bluementhal DT, Vogelbaum MA, Aldape KD et al. RTOG 0825: Phase III double-blind placebo-controlled trial evaluating bevacizumab (Bev) in patients (Pts) with newly diagnosed glioblastoma (GBM). J Clin Oncol 2013; 31: Suppl(abstr 1).
3. Lassen U, Sorensen M, Gaziel TB, Hasselbalch B, Poulsen HS . Phase II study of bevacizumab and temsirolimus combination therapy for recurrent glioblastoma multiforme. Anticancer Res 2013; 33: 1657–1660.
4. Gao BA, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal 2013; 6: pl1.
5. Vitucci M, Karpinich NO, Bash RE, Werneke AM, Schmid RS, White KK et al. Cooperativity between MAPK and PI3K signaling activation is required for glioblastoma pathogenesis. Neuro Oncol 2013; 15: 1317–1329.
Cited by
83 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献